Proceedings of the American Thoracic Society Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Donohue, J. F.
Right arrow Articles by Ohar, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Donohue, J. F.
Right arrow Articles by Ohar, J. A.
The Proceedings of the American Thoracic Society 1:152-160 (2004)
© 2004 The American Thoracic Society

Effects of Corticosteroids on Lung Function in Asthma and Chronic Obstructive Pulmonary Disease

James F. Donohue and Jill A. Ohar

Division of Pulmonary and Critical Care Medicine, University of North Carolina at Chapel Hill, Chapel Hill; and Division of Pulmonary and Critical Care Medicine, Wake Forest University, Winston-Salem, North Carolina

Correspondence and requests for reprints should be addressed to James F. Donohue, M.D., Department of Pulmonary and Critical Care Medicine, University of North Carolina at Chapel Hill, 4125 Bioinformatics Bldg., CB 7020, Chapel Hill, NC 27599-7020. E-mail: jdonohue{at}med.unc.edu

Both oral and inhaled corticosteroids have clinically significant effects on symptoms, exacerbations, health status, and lung function in asthma, and to a lesser extent in chronic obstructive pulmonary disease (COPD). Change in FEV1 does not correlate well with functional tests in COPD and may not be the best measure of response to treatment. Inhaled corticosteroids may be beneficial when added to a ß-agonist for treatment of acute asthma, and the efficacy of oral corticosteroids in this setting is well established. Oral corticosteroids inconsistently improve lung function in stable outpatients with COPD. Individual inhaled corticosteroids do not have a marked effect, but the combination of fluticasone propionate and salmeterol and the combination of budesonide plus formoterol seem to improve FEV1 over treatment with the individual components. In addition, there is convincing evidence for the use of systemic corticosteroids during acute exacerbations of COPD. Some evidence suggests that patients with COPD who respond to corticosteroids have eosinophilic inflammation and other attributes of an asthma phenotype.

Key Words: acute exacerbations • dose–response relationship • FEV1 • inhaled corticosteroids • oral corticosteroids






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American Thoracic Society.